Show simple item record

dc.contributor.authorShakya, Mila
dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorPollard, Andrew J
dc.date.accessioned2022-01-24T15:47:28Z
dc.date.available2022-01-24T15:47:28Z
dc.identifier.urihttp://hdl.handle.net/10713/17761
dc.description.abstractLow- and middle-income countries face a high burden of typhoid and paratyphoid fever due to poor water quality and inadequate sanitation. The World Health Organization (WHO) recommends the use of typhoid conjugate vaccines (TCV) in endemic settings and Gavi, the Vaccine Alliance, supports TCV introduction. There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. Countries should assess disease burden and consider introduction of TCV for programmatic use. Several paratyphoid vaccine candidates are in early stages of development. An effective bivalent vaccine would be the most efficient way to control typhoid and paratyphoid fever.en_US
dc.description.urihttps://doi.org/10.1093/infdis/jiab393en_US
dc.description.urihttp://www.ncbi.nlm.nih.gov/pmc/articles/pmc8687069/en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofJournal of Infectious Diseasesen_US
dc.rights© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.en_US
dc.subjectparatyphoid feveren_US
dc.subjecttyphoid conjugate vaccinesen_US
dc.subjecttyphoid feveren_US
dc.titleProspects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/infdis/jiab393
dc.identifier.pmid34374785
dc.source.journaltitleThe Journal of infectious diseases
dc.source.volume224
dc.source.issue12 Suppl 2
dc.source.beginpageS770
dc.source.endpageS774
dc.source.countryUnited States


This item appears in the following Collection(s)

Show simple item record